Member Info for imnotsosure

What's the Monday update? Ta.

what's the Monday update? Thanks.

Has a ~30% in SBTX, market cap of 21m. Currently on the way down, but interesting none the less.

https://www.skinbiotherapeutics.com/investor-relations/shares-in-issue-shareholder-information/

Well said. Up on no news. Down on no news. The company, their technology and prospects are the same as a week ago.

Steady on. Is that a 52 week high? Been going sideways since May-ish.

Andybear47: it looks like we've similar tastes... Ilika & N4P are in my PF too. Ilika are not far from me - I live near Romsey. Wonder if a small shareholder could ask for a visit... :-) It would be good to understand the uses /plus/minus of solid state batteries for IoT sensors vs the battery-free alternative (which collecting energy from vibrations etc.). Slightly off topic. Sorry!

Anyone want £29 of stuff for £20?

The discount to Nav on this stock it wider than the atlantic.

I guess PSH share holders will end up with a stake in the spac?

I made an ISA purchase a couple of days ago after watching the CEO talk. I optimistic for this stock over the next few years and who needs to pay capital gains... :-)

Cross fingers for nice steady gains, no traders. The trouble with large jumps is I never know whether to hold on or sell. Sometimes the spike is 'as good as it gets' for years. A nice smooth upward move - something like Maxcyte would be perfect! Anyway x-fingers.

Agreed. The tech has very interesting prospects. Next stop appointment of manufacturing partners, if I've understood correctly.

Thanks for the updates Monkshood. I bought some GCP and Empiric a few weeks back. Both my offspring will be at uni this autumn, and the accommodation costs are painful. One pays 5.5K the other £7K . So taking note of this, and the post-crash price of the shares, I thought I'd get some of this back by becoming a shareholder. Working OK so far!

Hi both.

I too hold equal amounts of HPVE + PIN. According to the HL app, discount to NAV averages out at -22.9% for PIN and -23.7% for HVPE. Don't know over what period this is. But it looks like long term discounts are the norm for these type of stocks? They're currently trading at not far off these discounts - despite the performance over the years. The question of discounts was raised in an interview with PIN (the funds fanatic podcast of the 14th July - on Spotify and perhaps elsewhere). Worth a listen if you haven't already.

Oakley is on an even crazier discount of -35% (did narrow recently, but then dropped back again). Good performance from them too - I'm also a holder.

I've given up hope of the discounts narrowing - I'm beginning to wonder if this is the way it is. Views?

The other one on a huge discount is Pershing Square (-32%) - not private equity in this case. Perhaps the fund manager is the 'issue' here? Bill Ackman. Though for me his recent record was the attraction - his trade in March was nothing short (!) of brilliant, and made shareholders a couple of billion.

Anyway... I've turned the discount frustration into a positive - I find the discounts reassuring - how low can a share go with a NAV that far ahead? A bit of value to balance out the biotech stocks in my portfolio!

All the best.
(my 'handle' refers the the mental torture I go through before buying/selling!)

Thank you for your reply. I'm trying to establish a factual & balance view, so counter points are very welcome.

According to this website the FCN process is quite quick. But the 120 days won't include gathering the testing data.

https://www.smithers.com/resources/2016/apr/fcn-system-quickest-route-to-regulatory-approval

'The FCN process is also relatively quick. Once the notification has been submitted to the FDA, it has 120 days to accept or reject the submission. If this deadline is not met, the product is automatically considered legal.'

I take the point about FDA approval being a plus / recognised outside the US.

So, the 'dragon's den' questions are...

The recent results for killing coronavirus on a surface including d2p is good news for sure, but does this give SYM advantage in the market? What evidence and approvals might be needed?

Is the use of zinc pyrithione to treat materials unique to SYM? A google reveals masks on the market treated with silver (antibacterial) and also with zinc pyrithione. So treatment of materials / fabric isn't unique to SYM. So, given that the active ingredient is known, not produced by SYM, and is widely available, what is to prevent any other business doing what they've done? Unique technology or IP would be best, though not vital if they have first mover advantage, or it is cheaper for their customers to buy d2p vs. make their own?

Regarding the bread packaging end use, it certainly it could be cheaper, easier and quicker to buy a product with FDA approval than go to the time and cost of doing it. Finally, the EU. FDA approval is a USA thing only. In the EU you can use the zinc compound. If used to protected a product against mould etc, then there aren't any big barriers from an EU regulations perspective. However, if active isn't there to protect the product itself (but to kill something external to the product), then the product may need registration in the EU. Not a problem, but it does take time and money.

Finally, a note on SYM's other technology - oxy biodegradable plastics. Do they have any IP here? The way this works is well know, you can read all about it on Wikipedia.

This is here (from the British Plastics Federation) isn't very positive...
https://www.bpf.co.uk/press/biodegradable-and-oxo-biodegradable-plastics.aspx
"Based on the evidence, the BPF believes Biodegradable and oxodegradable plastics are concepts that may resonate with some of the general public but they do not provide a viable solution to reducing the amount of plastic that wrongly ends up in the natural environment. These materials do not currently fully break down in the marine environment and could even cause harm during this process."

From <https://www.bpf.co.uk/press/biodegradable-and-oxo-biodegradable-plastics.aspx>

Anyone have anything to add?
Thanks for reading.

I've been doing some research into the d2p products. Comments welcome, as I could have missed something.

SYM has a series of product under the brand d2p. The one of recent interest is plastic with an additive that has antibacterial, anti-mould and, according to the recent independent lab report, antivirus properties.
Antimicrobial product:
https://www.symphonyenvironmental.com/wp-content/uploads/2020/07/Antimircobial-Optimised-1.pdf

This product sheet mentions the FDA approval for bread (though there is another one dedicated to that too). Searching around on the FDA site, I found an approval for SYM, for the antimould bread packaging. The active ingredient is Zinc pyrithione. A commonly used antimould (used in paints to help prevent mould growing on the wall in damp bathroom, for example. It is also used in anti dandruff shampoo).

Is the bread application unique to SYM? From the FDA website..

"According to Section 409(h)(1)(C) of the Federal Food, Drug, and Cosmetic Act, food contact substance notifications (FCNs) are effective only for the listed manufacturer and its customers. Other manufacturers must submit their own FCN for the same food contact substance and intended use."
https://www.accessdata.fda.gov/scripts/fdcc/?set=FCN&id=2031&sort=FCN_No&order=DESC&startrow=1&type=basic&search=Bread

So, it looks like other companies could potentially apply for and receive the same authorisation, for bread or other food applications.

Anti-viral too?
From the RNS.."Symphony Environmental Technologies Plc (AIM: SYM), is pleased to announce positive antiviral test results from Eurofins Laboratories for its d2p antimicrobial masterbatch technology."

So, it is the antimicrobial product that was tested and found to work on bovine coronavirus. So zinc pyrithione is the magic ingredient (probably...). Has anyone else found this compound to work on a virus? Yes. E.g. https://pubmed.ncbi.nlm.nih.gov/21079686/

So, the 'dragon's den' questions are... in part 2 of this note

Half year today
Nav 356
38% of NAV is cash